Civitas Therapeutics Email Format

BiotechnologyMassachusetts, United States11-50 Employees

Civitas Therapeutics is a privately held biotechnology company based in Chelsea, Massachusetts, focused on developing inhaled therapeutics using its ARCUS dry powder pulmonary delivery platform. Its lead program, CVT-301, aims to provide rapid and reliable relief from intermittent motor fluctuations in Parkinson’s disease patients when used as an adjunctive PRN therapy. The ARCUS system combines a dry powder formulation with a simple, breath-actuated device to deliver large, precise doses independent of inspiratory flow, supported by a substantial intellectual property portfolio. The company operates within the biopharmaceutical research sector, concentrating on creating inhaled treatments with the potential to address unmet needs in respiratory and neurological conditions. Civitas Therapeutics is privately held and affiliated with a broader ecosystem of biopharma companies in the region. A recent development noted is the publicized acquisition context involving Civitas Therapeutics and related assets in the industry landscape.

Sign up for free to view info

Company overview Employee directory